Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 3/20 | 0.36 |
| ▸ | KCNQ2 | O43526 | 3/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | ACACB | O00763 | 4/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4096599 | 1.00 | KCNQ3 (0.36) | KCNQ3KCNQ2GPR119KDM4EUSP2 | |
| SCHEMBL4113956 | 0.78 | GPR119 (0.61) | GPR119CYP2C19 | |
| SCHEMBL4113959 | 0.78 | GPR119 (0.61) | GPR119CYP2C19 | |
| SCHEMBL356075 | 0.77 | GPR119 (0.55) | GPR119KCNH2 | |
| SCHEMBL13194797 | 0.76 | GPR119 (0.38) | KCNQ3KCNQ2GPR119KCNH2 | |
| SCHEMBL354301 | 0.74 | GPR119 (0.39) | KCNQ3KCNQ2GPR119KCNH2 | |
| SCHEMBL460939 | 0.73 | MAPK8 (0.42) | GPR119KCNH2 | |
| SCHEMBL4106232 | 0.69 | GPR119 (0.52) | GPR119 | |
| SCHEMBL150107 | 0.69 | CYP11B2 (0.42) | GPR119KCNH2 | |
| SCHEMBL2430251 | 0.69 | GPR119 (0.36) | GPR119KDM4EKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013201-B1 | HETEROCYCLIC GPCR AGONISTS | PROSIDION LTD (GB) | 2012-07-25 | — | — | EP | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221639-A1 | Heterocyclic GPCR Agonists | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221639-A1 | Heterocyclic GPCR Agonists | GPR119, GCGR, GLP1R | KCNQ3 1056/4885KCNQ2 945/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.